Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Large Growth in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 53,761 shares, an increase of 141.5% from the March 31st total of 22,264 shares. Currently, 2.1% of the company’s stock are sold short. Based on an average daily trading volume, of 94,230 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CDIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardio Diagnostics in a report on Monday, December 29th. Wall Street Zen upgraded Cardio Diagnostics to a “hold” rating in a report on Saturday, March 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Cardio Diagnostics Price Performance

NASDAQ CDIO traded up $0.01 during trading on Monday, reaching $1.83. The company’s stock had a trading volume of 16,407 shares, compared to its average volume of 3,156,072. The firm has a fifty day moving average of $2.83 and a 200 day moving average of $2.91. Cardio Diagnostics has a one year low of $0.97 and a one year high of $15.00. The stock has a market capitalization of $5.42 million, a PE ratio of -0.49 and a beta of 2.70.

Cardio Diagnostics (NASDAQ:CDIO) last posted its quarterly earnings data on Friday, March 13th. The company reported ($0.80) earnings per share (EPS) for the quarter. Cardio Diagnostics had a negative return on equity of 71.75% and a negative net margin of 40,612.50%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC acquired a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned approximately 1.07% of Cardio Diagnostics as of its most recent SEC filing. 8.06% of the stock is owned by hedge funds and other institutional investors.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.